SHERI DENHAM: Open Payments
NPI 1295279214 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,765 in 53 payments from 12 companies in 2025. Trend: 2023 $792 · 2024 $689 · 2025 $3,765
Speaker / faculty: $2,403Food & beverage: $1,028Travel & lodging: $334
| Company | Payments | Amount |
|---|---|---|
| Indivior Inc. | 11 | $2,897 |
| ABBVIE INC. | 12 | $215 |
| Braeburn Inc. | 7 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $116 |
| Novo Nordisk Inc | 4 | $99 |
| Alkermes, Inc. | 4 | $80 |
| Lundbeck LLC | 3 | $68 |
| Lilly USA, LLC | 2 | $45 |
| Vanda Pharmaceuticals Inc. | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 1 | $26 |
Products named: SUBLOCADE, VRAYLAR, BRIXADI, CAPLYTA, ARISTADA, Rybelsus, REXULTI, MOUNJARO.
Industry payments across MD — which companies pay providers there.
